Grant: Engage Grants Program
University of Toronto
$25,000.00
Development of a novel oral proteasome inhibitor
EF 2011-12
Résumé
The proteasome is a complex of enzymes that works to rid the cell of excess proteins. Blocking the proeasome with drugs such as Bortezomib kills cancer cells. This drug has also been proven to be clinically useful in treating patients with myeloma and lymphoma. While a useful drug, most patients do not respond to Bortezomib and almost all who respond ultimately relapse. Therefore, novel proteasome inhibitors would be clinically useful. Here, we propose a project in collaboration with Fluorinov Pharma to develop efficacious and orally active inhibitors that have fewer side effects than conventional proteasome inhibitors. An orally-administered inhibitor has the potential advantage of being easily incorporated into multi-drag treatment regimens, administered on a daily schedule if necessary, and would have greater commercial acceptance greater commercial acceptance in the Ontario marketplace. In this proposal we will test the proteasome inhibitor developed by Fluorinov Pharma and determine whether it inhibits this enzyme complex. We will also conduct preclinical studies using myeloma cell lines and mouse models of myelome to evaluate its potential efficacy for the treatment of this disease. Thus, through this work, we will advance a novel drug towards clinical trial for patients with myeloma.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
411257-2010
Name nom
Schimmer, Aaron
Department département
Medicine, Department of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2010
Award amount
25000
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Partie
1
Nb partie
1
Application title
Development of a novel oral proteasome inhibitor
Keyword
NSERC
Application summary
The proteasome is a complex of enzymes that works to rid the cell of excess proteins. Blocking the proeasome with drugs such as Bortezomib kills cancer cells. This drug has also been proven to be clinically useful in treating patients with myeloma and lymphoma. While a useful drug, most patients do not respond to Bortezomib and almost all who respond ultimately relapse. Therefore, novel proteasome inhibitors would be clinically useful. Here, we propose a project in collaboration with Fluorinov Pharma to develop efficacious and orally active inhibitors that have fewer side effects than conventional proteasome inhibitors. An orally-administered inhibitor has the potential advantage of being easily incorporated into multi-drag treatment regimens, administered on a daily schedule if necessary, and would have greater commercial acceptance greater commercial acceptance in the Ontario marketplace. In this proposal we will test the proteasome inhibitor developed by Fluorinov Pharma and determine whether it inhibits this enzyme complex. We will also conduct preclinical studies using myeloma cell lines and mouse models of myelome to evaluate its potential efficacy for the treatment of this disease. Thus, through this work, we will advance a novel drug towards clinical trial for patients with myeloma.